[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:bladder-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":312,"states":321},"Bladder Carcinoma",153,135,[8,16,23,30,37,43,49,55,61,67,73,79,85,91,97,102,108,114,120,127,133,139,145,152,158,164,170,176,181,187,193,199,205,211,217,223,229,235,241,247,253,259,265,271,277,283,289,295,301,307],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06703476","A Study of Surgical Techniques During Cystectomy",[12],"Phase 3","RECRUITING","2026-08-26T02:17:15.156099Z","2026-07-19T19:36:05.035662Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06704191","In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial",[20],"Phase 1\u002FPhase 2","2026-08-26T02:15:00.557154Z","2026-05-05T02:43:29.677646Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07322263","Intravesical GEM\u002FDOCE for HR BCG-Unresponsive NMIBC",[27],"Phase 2","2026-08-26T02:17:33.807405Z","2026-05-05T02:43:29.513094Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT06764095","Enfortumab Vedotin and Pembrolizumab With Cystectomy and\u002For Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial",[34],"Phase 4","2026-08-26T02:17:03.534765Z","2026-05-05T02:43:29.500054Z",{"nct_id":38,"title":39,"phases":40,"status":13,"updated_at":41,"content_modified":42},"NCT07048496","Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support",[],"2026-08-26T02:16:57.705506Z","2026-05-05T02:43:29.200098Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT06809140","Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer",[27],"2026-08-26T02:18:45.196599Z","2026-05-05T02:43:29.160849Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT04442724","Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy",[],"2026-08-26T02:18:07.037408Z","2026-05-05T02:43:28.984627Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06689176","Chlorhexidine Antiseptic Irrigation of the Bowel Segment During Radical Cystectomy and Urinary Diversion",[],"2026-08-26T02:18:57.189473Z","2026-05-05T02:43:28.879266Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06571708","Gemcitabine\u002FCisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)",[27],"2026-08-26T02:19:27.519777Z","2026-05-05T02:43:28.725916Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06290687","Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy",[27],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:28.704029Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05792722","Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy",[],"2026-08-26T02:16:26.411851Z","2026-05-05T02:43:28.652652Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06637423","A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)",[20],"2026-08-26T02:18:02.701182Z","2026-05-05T02:43:28.341163Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT07097142","Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study",[12],"2026-08-26T02:16:17.877565Z","2026-05-05T02:43:28.205368Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07222488","A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)",[20],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:28.130472Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":65,"content_modified":101},"NCT06545955","A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer",[12],"2026-05-05T02:43:28.118589Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT05951179","Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer",[27],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:27.965164Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT06567743","Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC",[27],"2026-08-26T02:19:19.975067Z","2026-05-05T02:43:27.959967Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT07000084","Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy",[12],"2026-08-26T02:15:11.740957Z","2026-05-05T02:43:27.931255Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":125,"content_modified":126},"NCT05483868","A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer",[124],"Phase 1","2026-08-03T02:23:47.185024Z","2026-05-05T02:43:27.829157Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT05519241","A Phase I Intravesical PPM Therapy for NMIBC",[124],"2026-08-26T02:15:42.447052Z","2026-05-05T02:43:27.730272Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT06488222","Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer",[27],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:27.621070Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT06493370","Intravenous Ascorbate Plus Gemcitabine\u002FCarboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer",[27],"2026-08-26T02:15:39.267524Z","2026-05-05T02:43:27.620494Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":150,"content_modified":151},"NCT06190197","Prophylactic Antibiotics in Cystectomy With Diversion",[149],"Early Phase 1","2026-08-26T02:15:02.712396Z","2026-05-05T02:43:27.320738Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT03216525","Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol",[12],"2026-08-26T02:17:38.215063Z","2026-05-05T02:43:27.291531Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT06770582","Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial",[27],"2026-08-26T02:15:59.318403Z","2026-05-05T02:43:27.088419Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT06470282","Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer",[20],"2026-08-26T02:17:12.307088Z","2026-05-05T02:43:26.924887Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":174,"content_modified":175},"NCT05833867","Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer",[124],"2026-08-26T02:16:24.135291Z","2026-05-05T02:43:26.915423Z",{"nct_id":177,"title":178,"phases":179,"status":13,"updated_at":28,"content_modified":180},"NCT06586255","Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer",[124],"2026-05-05T02:43:26.898408Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT06417190","Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology",[27],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:26.896748Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT06919965","A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer",[12],"2026-08-26T02:18:46.948970Z","2026-05-05T02:35:31.753313Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT07206225","A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer",[124],"2026-08-26T02:18:12.612955Z","2026-05-05T02:35:31.602441Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT06337942","Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study",[],"2026-08-26T02:17:35.666428Z","2026-05-05T02:43:29.077282Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":209,"content_modified":210},"NCT07337525","A First in Human Study of PLT012 in Participants With Solid Tumor Cancers",[124],"2026-08-26T02:15:57.572488Z","2026-05-05T02:43:27.075578Z",{"nct_id":212,"title":213,"phases":214,"status":13,"updated_at":215,"content_modified":216},"NCT05503797","A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations",[27],"2026-08-26T02:19:21.761002Z","2026-07-30T01:46:14.464355Z",{"nct_id":218,"title":219,"phases":220,"status":13,"updated_at":221,"content_modified":222},"NCT06814496","Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors",[20],"2026-08-26T02:15:38.131683Z","2026-07-24T01:27:14.891188Z",{"nct_id":224,"title":225,"phases":226,"status":13,"updated_at":227,"content_modified":228},"NCT06529822","Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease",[124],"2026-08-26T02:15:24.145250Z","2026-07-19T19:36:05.068854Z",{"nct_id":230,"title":231,"phases":232,"status":13,"updated_at":233,"content_modified":234},"NCT06580002","Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial",[27],"2026-08-26T02:15:04.877798Z","2026-07-19T19:36:05.038415Z",{"nct_id":236,"title":237,"phases":238,"status":13,"updated_at":239,"content_modified":240},"NCT07578571","A Phase 1 Study of IM-1617 in Participants With Advanced Cancer",[124],"2026-08-26T02:18:48.678868Z","2026-05-29T15:36:40.196396Z",{"nct_id":242,"title":243,"phases":244,"status":13,"updated_at":245,"content_modified":246},"NCT07197671","Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer",[124],"2026-08-26T02:15:58.452248Z","2026-05-05T02:43:29.735881Z",{"nct_id":248,"title":249,"phases":250,"status":13,"updated_at":251,"content_modified":252},"NCT05902988","A Phase I\u002FII Study of VLS-1488 in Subjects With Advanced Cancer",[20],"2026-08-26T02:17:13.277148Z","2026-05-05T02:43:29.683485Z",{"nct_id":254,"title":255,"phases":256,"status":13,"updated_at":257,"content_modified":258},"NCT07050771","Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery",[27],"2026-08-26T02:18:39.640967Z","2026-05-05T02:43:29.665036Z",{"nct_id":260,"title":261,"phases":262,"status":13,"updated_at":263,"content_modified":264},"NCT06242470","A Study of MGC026 in Participants With Advanced Solid Tumors",[124],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:29.659697Z",{"nct_id":266,"title":267,"phases":268,"status":13,"updated_at":269,"content_modified":270},"NCT06444815","A Study of VET3-TGI in Patients With Solid Tumors",[124],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:29.507169Z",{"nct_id":272,"title":273,"phases":274,"status":13,"updated_at":275,"content_modified":276},"NCT07027488","AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors",[124],"2026-08-26T02:17:57.117858Z","2026-05-05T02:43:29.505679Z",{"nct_id":278,"title":279,"phases":280,"status":13,"updated_at":281,"content_modified":282},"NCT05533697","Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors",[20],"2026-08-26T02:19:04.543908Z","2026-05-05T02:43:29.371442Z",{"nct_id":284,"title":285,"phases":286,"status":13,"updated_at":287,"content_modified":288},"NCT07030712","A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)",[124],"2026-08-26T02:19:11.399072Z","2026-05-05T02:43:29.325195Z",{"nct_id":290,"title":291,"phases":292,"status":13,"updated_at":293,"content_modified":294},"NCT04235777","Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies",[124],"2026-08-03T03:29:32.085476Z","2026-05-05T02:43:29.189537Z",{"nct_id":296,"title":297,"phases":298,"status":13,"updated_at":299,"content_modified":300},"NCT05756569","Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology",[27],"2026-08-26T02:16:11.347936Z","2026-05-05T02:43:29.051565Z",{"nct_id":302,"title":303,"phases":304,"status":13,"updated_at":305,"content_modified":306},"NCT03866382","Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors",[27],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:29.038812Z",{"nct_id":308,"title":309,"phases":310,"status":13,"updated_at":89,"content_modified":311},"NCT03740256","Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors",[124],"2026-05-05T02:43:28.644039Z",[313,317],{"biomarker":314,"count":315,"slug":316},"ERBB2 Gene",5,"erbb2-gene",{"biomarker":318,"count":319,"slug":320},"Programmed Cell Death 1 Ligand 1",3,"programmed-cell-death-1-ligand-1",[322,326,330,334,337,341,345,349,353,357,361,365,369,372,375,379,383,387,391,394,397,400,404,407],{"state":323,"count":324,"slug":325},"California",60,"california",{"state":327,"count":328,"slug":329},"Texas",50,"texas",{"state":331,"count":332,"slug":333},"Florida",37,"florida",{"state":335,"count":332,"slug":336},"New York","new-york",{"state":338,"count":339,"slug":340},"Ohio",32,"ohio",{"state":342,"count":343,"slug":344},"Massachusetts",30,"massachusetts",{"state":346,"count":347,"slug":348},"Pennsylvania",28,"pennsylvania",{"state":350,"count":351,"slug":352},"Maryland",27,"maryland",{"state":354,"count":355,"slug":356},"Illinois",25,"illinois",{"state":358,"count":359,"slug":360},"Tennessee",24,"tennessee",{"state":362,"count":363,"slug":364},"New Jersey",23,"new-jersey",{"state":366,"count":367,"slug":368},"Michigan",21,"michigan",{"state":370,"count":367,"slug":371},"Missouri","missouri",{"state":373,"count":367,"slug":374},"North Carolina","north-carolina",{"state":376,"count":377,"slug":378},"Colorado",20,"colorado",{"state":380,"count":381,"slug":382},"Minnesota",19,"minnesota",{"state":384,"count":385,"slug":386},"Washington",17,"washington",{"state":388,"count":389,"slug":390},"Indiana",15,"indiana",{"state":392,"count":389,"slug":393},"Kansas","kansas",{"state":395,"count":389,"slug":396},"South Carolina","south-carolina",{"state":398,"count":389,"slug":399},"Virginia","virginia",{"state":401,"count":402,"slug":403},"Arizona",13,"arizona",{"state":405,"count":402,"slug":406},"Georgia","georgia",{"state":408,"count":409,"slug":410},"Wisconsin",12,"wisconsin"]